Please use this identifier to cite or link to this item:
Title: Treating through of drug-associated exanthem in drug allergy management: current evidence and clinical aspects.
Austin Authors: Trubiano, Jason ;Soria, Angèle;Torres, Maria J;Trautmann, Axel
Affiliation: Medicine (University of Melbourne)
Sorbonne Universités, Paris, France
Andalusian Center for Nanomedicine and Biotechnology - BIONAND, Malaga, Spain
Allergy Unit, IBIMA-Regional University Hospital of Malaga UMA, Malaga, Spain
Centre d'Immunologie et des Maladies Infectieuses - Paris (Cimi-Paris), INSERM U1135, Paris, France
Service de Dermatologie et d'Allergologie, Hôpital Tenon, Paris HUEP, APHP, Paris, France
Centre for Antibiotic Allergy and Research
Department of Dermatology and Allergy, University Hospital Würzburg, Würzburg, Germany
Infectious Diseases
Issue Date: 17-Apr-2021
Date: 2021-04-17
Publication information: The Journal of Allergy and Clinical Immunology. In Practice 2021; online first: 17 April
Abstract: In the setting of an acute cutaneous adverse drug reaction (CADR) there is increasing interest in selected phenotypes and hosts to continue drug therapy, especially in settings where there are limited therapeutic options. This concept of "treating through", defined as the continued use of a drug in the setting of, in particular maculopapular exanthema (MPE), potentially avoids unnecessary drug discontinuation. A review of the recent literature, historical viewpoints and expert opinion are provided within to form recommendations and algorithms for a "treating through" approach.
DOI: 10.1016/j.jaip.2021.04.008
Journal: The Journal of Allergy and Clinical Immunology. In Practice
PubMed URL: 33878455
Type: Journal Article
Subjects: Drug Allergy
drug-associated exanthem
Appears in Collections:Journal articles

Show full item record

Page view(s)

checked on Sep 28, 2023

Google ScholarTM


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.